Skip to main content


Figure 4 | Diabetology & Metabolic Syndrome

Figure 4

From: Liraglutide counteracts obesity and glucose intolerance in a mouse model of glucocorticoid-induced metabolic syndrome

Figure 4

Once daily injections of liraglutide do not affect the increment of pancreatic beta-cells mass seen in corticosterone-exposed mice. Male C57Bl/6J mice were treated with 1% ethanol (vehicle, white bars) or 100 μg/ml corticosterone (GC, black bars) via the drinking water together with once-daily injections of either PBS (unstriped bars) or liraglutide (Lira) at a final dose of 0.3 mg per kg body weight (striped bars) for five consecutive weeks (n = 5-6). After treatment the pancreatic glands were dissected and processed for histology. Tissue sections were immunostained for insulin-positive cells (A). Morphometric analysis was used to determine islet density (B), relative beta-cell mass (C) and absolute beta-cell mass either expressed in mg (D) or as μg per g body weight (E). Images in (A) are representative pictures of insulin staining in the examined tissue (40 × magnification, bar represents 500 μm). Data is shown as mean ± s.e.m. A * denotes a significant (p < 0.05) effect of corticosterone treatment.

Back to article page